Hong-Yuan Li
Overview
Explore the profile of Hong-Yuan Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu Y, Li J, Li H, Deng S, Jia A
Synth Syst Biotechnol
. 2021 Nov;
6(4):360-368.
PMID: 34786511
Quorum sensing (QS) plays an essential role in virulence factor production, biofilm formation, and antimicrobial resistance. As a potent QS inhibitor, hordenine can inhibit both QS and biofilm formation in...
12.
Peng P, Chen J, Han Y, Chen X, Li H, Hu C, et al.
BMC Surg
. 2021 Oct;
21(1):378.
PMID: 34702227
Background: It was controversial to operate on the primary site of breast cancer (BC) with bone metastasis only. We investigated the impact of surgery on BC patients with bone metastases...
13.
Han Y, Yi Z, Yu P, Wang W, Ouyang Q, Yan M, et al.
J Oncol
. 2021 Sep;
2021:6621722.
PMID: 34567118
Objective: To better understand the status of medical treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the differences between the Chinese and the international clinical practice....
14.
Wang K, Sun J, Wu Q, Li Z, Li D, Xiong Y, et al.
NPJ Breast Cancer
. 2020 Aug;
6:36.
PMID: 32821804
Inflammation-modulating nutrients and inflammatory markers are established cancer risk factors, however, evidence regarding the association between post-diagnosis diet-associated inflammation and breast cancer survival is relatively sparse. We aimed to examine...
15.
Yi Z, Yu P, Zhang S, Wang W, Han Y, Ouyang Q, et al.
Int J Cancer
. 2020 Jul;
148(3):692-701.
PMID: 32700765
Although receptor status including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) of the primary breast tumors was related to the prognosis of breast...
16.
Zou B, Liu J, Li H, Xu Z, Li H, Li H, et al.
Eur J Med Res
. 2020 Mar;
25(1):7.
PMID: 32183885
Objective: Secondary hyperparathyroidism (SHPT) is a common complication of end-stage renal disease (ESRD), and part of SHPT patients need receive parathyroidectomy (PTX). However, as an important postoperative complication of SHPT,...
17.
Xu Z, Luo F, Wang Y, Zou B, Man Y, Liu J, et al.
Cancer Chemother Pharmacol
. 2019 Nov;
85(1):61-67.
PMID: 31745592
Purpose: Chemotherapy-related cognitive impairments in breast cancer patients were usually reported through cognitive questionnaires or scales which may be subjective and insensitive. This study is to assess the effect of...
18.
Wang K, Wu Y, Zhang X, Chen L, Zhu W, Zhang A, et al.
Biomed Res Int
. 2019 May;
2019:3692093.
PMID: 31119166
Introduction: Clinicopathologic and prognostic significance of body mass index (BMI) in breast cancer (BC) patients remained conflicting. We aimed to investigate and modify the impact of BMI on clinicopathological significance...
19.
Wang K, Shi Y, Li Z, Xiao Y, Li J, Zhang X, et al.
Eur J Surg Oncol
. 2019 Mar;
45(8):1364-1372.
PMID: 30837102
Introduction: Role of surgery in the management of de novo stage IV breast cancer (BC) remains controversial. We aimed to determine the survival benefit of primary surgery on the basis...
20.
Wang K, Li H, Xiong Y, Shi Y, Li Z, Li J, et al.
Cancer Med
. 2019 Jan;
8(2):686-700.
PMID: 30677255
Purpose: Accumulating evidence indicated that triple-negative breast cancer (TNBC) can stimulate stronger immune responses than other subtypes of breast cancer. We hypothesized that integrating immune-related genomic signatures with clinicopathologic factors...